The Commerce Department has set a zero tariff on listed specialty medicines from 19 jurisdictions, carving them out of the 100 percent duty President Trump ordered on patented drugs in April. The exemption took effect at 12:01 a.m. Eastern on September 29, the date the tariff began for most drugmakers. Generic medicines were never part of that tariff, so the carve-out changes nothing for them. The result is a split market: orphan-drug, plasma, fertility and gene-therapy products from the listed places enter duty-free, while other patented imports can still face charges of 10 to 100 percent.
Trump signed Proclamation 11020 on April 2 under Section 232, the trade law that lets a president restrict imports on national-security grounds. It put a 100 percent tariff on patented pharmaceuticals and the ingredients used to make them. The duty began July 31 for drugmakers named on a list attached to the proclamation and on September 29 for every other company. Lower rates apply to certain countries and to companies with Commerce-approved plans to build production in the United States.
Nine kinds of specialty medicine get the zero rate
Commerce’s Bureau of Industry and Security spelled out the exemption in a notice published in the Federal Register on September 23, signed by Deputy Assistant Secretary for Technology Security Jessica Curyto. The zero rate covers nine product types: drugs whose every approved use is for a rare disease, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapies, gene therapies, antibody-drug conjugates, countermeasures against chemical, biological, radiological and nuclear threats, and animal health products.
The 19 jurisdictions are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland together with Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. The notice counts the European Union as one entry and lists Switzerland and Liechtenstein as one. A patient needs two facts to know whether a medicine is affected: whether it falls in one of the nine groups, and where it is made. An antibody-drug conjugate made in Japan, for example, falls in a listed group, while an ordinary patented tablet from Japan does not and stays at the 15 percent rate.
Commerce says the list of 19 jurisdictions can change in a future notice, and the zero rate follows it.
Get each new number in one short weekday email →
The notice sets two ways to reach the zero rate. A product qualifies if it comes from a jurisdiction that has a current or forthcoming trade and security framework agreement with the United States under Executive Order 14346. It can also qualify if Commerce, after consulting the U.S. Trade Representative and the Department of Health and Human Services, approves it for an urgent U.S. health need. That second route is decided one product and one company at a time.
Generics were left out in April
The exclusion is written into the original action. In Proclamation 11020, Trump decided not to adjust imports of generic pharmaceuticals, and the text says they “shall not be subject to tariffs pursuant to section 232 at this time.” The proclamation says that decision covers biosimilars, the near-copies of complex biologic drugs. The 100 percent rate in the same document applies to patented products listed in an annex, which is why a generic never entered the tariff to begin with.
Commerce repeated the point in its September notice, which says the Section 232 pharmaceutical tariffs “do not apply to generic pharmaceutical products.” The notice also makes one technical change on that front. It widens the definition of a generic pharmaceutical article to include an unpatented animal health product, so those items stay outside the tariff too. Commerce describes the edit as a correction, not a new exemption.
The wording is not permanent. Both documents say “at this time,” and the proclamation directs the Commerce Secretary to report within one year on any circumstances that might warrant action on generics. Generics are excluded today because the president chose to exclude them, and that choice can be revisited. Neither document says it will be.
Where tariffs still apply to medicines
Outside the zero list, the April rates still stand. Under the proclamation, patented products from Japan, the European Union, South Korea and Switzerland with Liechtenstein carry a combined 15 percent rate, and the United Kingdom’s rate is 10 percent, with a path to zero under a future pricing agreement. Companies with Commerce-approved onshoring plans pay 20 percent, a rate that rises to 100 percent on April 2, 2030. The 100 percent rate applies to everyone else.
The proclamation also carries separate zero rates for companies that have signed most-favored-nation pricing agreements with the administration, which hold until January 20, 2029, and for U.S.-made pharmaceutical products. That means a brand-name drug can enter tariff-free through several routes, and the 19-jurisdiction list is only the one Commerce’s September notice spells out in detail.
The September notice also adds a zero rate for pharmaceuticals and ingredients used solely in clinical trials, research or other non-commercial work. Customs and Border Protection applies the adjustments when an importer files an entry summary and can ask for documents to check them. Requests for the urgent-need route go by email to pharma232@bis.doc.gov, and Commerce says each decision is “individual, fact-specific, company-specific.”
Telling a generic from a brand at the pharmacy
The tariff is charged to the importer at the border, and neither the proclamation nor the Commerce notice puts a price on a prescription. Whether any importer’s cost shows up at the pharmacy counter depends on the drug, the maker and the plan paying for it. A generic is the clearest case: it is outside the tariff in both documents.
The Food and Drug Administration says an approved generic must have the same active ingredient, strength, dosage form and route of administration as the brand-name drug and must be bioequivalent to it. Its generic drug facts page advises patients to ask a doctor or pharmacist about generic options, and a pharmacist can say whether a filled prescription is a generic or a brand.
Commerce has said a 60-day public comment notice will follow on the information collection behind the urgent-need requests, and the list of 19 jurisdictions can be rewritten in any later notice. The Federal Register entry for Docket No. 260918-0006, published at 91 FR 60360, is the document that would carry a change.
More Financial Reading
- 24 Ways to Stretch a $2,087 Social Security Check
- 17 Places to Find Your Share of the $4.25 Billion States Give Back
- 22 Ways Retirees Can Raise $1,000 Fast Without a Job
This article was prepared with AI assistance and reviewed against the cited public sources.